Significance Statement {#s1}
======================

Sleep apnea is associated with cognitive decline and neurologic disease. Intermittent hypoxia (IH), a hallmark consequence of sleep apnea, yet the mechanisms by which IH affects cognition is poorly understood. We show that a pro-oxidant state produced by HIF1a is a central factor causing IH-dependent impairment to spatial memory and synaptic plasticity. This work identifies potential targets for intervention in mitigating cognitive decline associated with sleep apnea.

Introduction {#s2}
============

The hippocampus is widely regarded for its importance in learning and memory and is frequently identified as a brain structure impacted by sleep apnea ([@B30]; [@B3]; [@B21]; [@B31]). As cognitive decline is a recognized comorbidity of sleep apnea ([@B34]; [@B32]; [@B11]; [@B7],[@B8]; [@B19]), changes to hippocampal physiology may have a significant role in disrupting cognition. Intermittent hypoxia (IH) is a hallmark of the sleep apnea and impairs spatial learning and memory ([@B28]; [@B14]). These impairments coincide with weakened synaptic plasticity in area CA1 of the hippocampus ([@B12]; [@B23]; [@B35]; [@B37]; [@B33]) and the production of oxidative stress in the brain ([@B22]; [@B5]). Impaired synaptic plasticity and oxidative stress have been implicated in causing IH-dependent deficits to cognition, but the mechanistic basis by which IH impairs learning and memory remains elusive.

The transcription factor, hypoxia inducible factor 1a (HIF1a) is a critical mediator of cellular adaptations to hypoxia, and is capable of promoting the generation of reactive oxygen species (ROS) that can lead to oxidative stress ([@B29]). IH increases HIF1a in the hippocampal formation ([@B5]; [@B33]). However, the role of IH-dependent HIF1a signaling on changes to the neurophysiological processes underlying cognition remains poorly understood. HIF1a signaling may have an important protective pro-survival role in the brain preserving function in response to the hypoxia experienced during IH. Alternatively, HIF1a may serve as a pro-oxidant transcription factor leading to oxidative stress and impaired neurophysiology. Here, we seek to resolve the role of HIF1a in IH-dependent changes to cognition and the synaptic plasticity. Our experiments demonstrate that enhanced HIF1a signaling promotes a pro-oxidant condition that impairs NMDA receptor (NMDAr)-dependent synaptic plasticity at the local circuit level and contributes deficits in spatial memory.

Materials and Methods {#s3}
=====================

Study approval {#s3A}
--------------

In accordance with National Institutes of Health guidelines, all animal procedures were performed in accordance with the University of Chicago animal care committee's regulations.

Animals {#s3B}
-------

Animals were housed in AAALAC-approved facilities with a 12/12 h light/dark cycle and given *ad libitum* access to food and water. Experiments were performed on wild-type mice and HIF1a^+/−^ ([@B16]; [@B25]) from both sexes (Postnatal day 50 to 80). Unless explicitly stated, no sex-based differences were observed throughout the experiments conducted. All animals were maintained on a C57BL/6 background. Automated genotyping was performed independently by a commercial service (Transnetyx Inc).

IH exposure {#s3C}
-----------

Male and female mice were exposed to chronic IH for 10 consecutive days (IH~10~). In brief, as previously described ([@B24]), the IH~10~ paradigm was performed in a special chamber during the light cycle and lasted 8 h/d (i.e., 80 IH cycles/d). A single hypoxic cycle was achieved by flowing 100% N~2~ into the chamber for ∼60 s (nadir O~2~ reached 4.5 ± 1.5%) and followed immediately by an air break (∼21% O~2~; 300 s).

In a subset of animals used for behavioral experiments, manganese (III) tetrakis(1-methyl-4-pyridyl) porphyrin (MnTMPyP; Enzo Life Sciences, catalog \#ALX-430--070) was administered via intraperitoneal injection at the beginning of each day before exposure to IH. Previous reports have indicated that dose of MnTMPyP at either 5 mg/kg ([@B25]) or 15 mg/kg ([@B17]) can mitigate the effects of IH in the nervous system. Therefore, the smaller dose (5 mg/kg, *n* = 9 mice) and the larger dose (15 mg/kg, *n* = 3 mice) were used but no differences were evident between dosage groups; and therefore, the data at the two concentrations were pooled.

Barnes maze {#s3D}
-----------

The Barnes maze was performed using a custom made opaque white circular acrylic platform (92.4 cm in diameter) with 20 equidistant holes (5.08 cm in diameter and 2.54 cm from the edge). The platform was elevated (30 cm from the floor) ground and surrounded by four identical walls (27.94 cm high). By default, each hole was closed with a fixed piece of opaque acrylic that could be removed to lead to a dark exit box. Lighting was achieved through diffuse overhead fluorescent lighting such that all holes were equally lit. An overhead camera was suspended above the maze allowing for video tracking. Data collection and *post hoc* analysis was performed using CinePlex Video Tracking System (Plexon).

As previously described ([@B6]), the task was performed using a 4-d protocol consisting of one training trial per day for three consecutive days and a probe trial on the fourth day. Barnes maze began on the seventh day of IH~10~ exposure with respective controls run at the same time. In IH mice, all training trials and the probe trial were conducted before IH exposure on days 7--10. For the training trials, all, but one of the holes (exit hole), were closed. Closed holes were defined as false exits in the training and probe trials. An exit box with a small ramp was placed directly underneath the exit hole. Animals were given a maximum of 6 min to locate the exit. If the mouse found and entered the exit before the 6-min mark, the trial ended. The time of exit was reported as total latency for the trial. If the mouse was unable to locate the exit by 6 min, they were gently guided to the exit and total latency for the trial was reported as 360 s. At end of each trials, the mouse was promptly returned to its home cage. During the probe trial, all holes were closed, and the animal was given 6 min to explore the maze. Latency to initial entry and distance to initial entry into the exit zone were reported. All subjects entered the exit zone during the probe trial. The total number of entries for each false exit and the exit were recorded and used to calculate entry probability.

Entry probability for each false exit and the exit zone during the probe trial was calculated by the following: $${EP_{n} = 100\text{\%} \times \frac{x_{n}}{x_{total}}},$$where *EP~n~*= entry probability for the exit zone; *x~n~*= number of entries into hole n; and *x~total~* = sum of entries into exit zone and false exits.

The entire arena was sanitized in-between trials. Following the end of behavioral testing, IH animals were immediately placed into the IH chamber for exposure.

Slice preparation {#s3E}
-----------------

As previously described ([@B17]), acute coronal hippocampal slices were prepared from mice unexposed to IH or from mice exposed to IH for 10 d. Tissue harvest occurred within 1--2 d following IH~10~. Mice were anesthetized with isoflurane and euthanized via rapid decapitation. The cerebrum was immediately harvested and blocked, rinsed with cold artificial CSF (aCSF), and mounted for vibratome sectioning. The mounted brain tissue was submerged in aCSF (4°C; equilibrated with 95% O~2~, 5% CO~2~) and coronal cortico-hippocampal brain slices (350 μ;m thick) were prepared. Slices were then immediately transferred into a holding chamber containing aCSF equilibrated with 95% O~2~, 5% CO~2~ (at 20.5 ± 1°C). Slices were allowed to recover for a minimum of one hour before recording and used up to eight hours following tissue harvest. The composition of aCSF was as following: 118 m[m]{.smallcaps} NaCl, 10 m[m]{.smallcaps} glucose, 20 m[m]{.smallcaps} sucrose, 25 m[m]{.smallcaps} NaHCO~3~, 3.0 m[m]{.smallcaps} KCl, 1.5 m[m]{.smallcaps} CaCl~2~, 1.0 m[m]{.smallcaps} NaH~2~PO~4~, and 1.0 m[m]{.smallcaps} MgCl~2.~

Extracellular recording of the field EPSP (fEPSP) {#s3F}
-------------------------------------------------

For electrophysiological recordings, slices were transferred to a recording chamber with recirculating aCSF (30.5 ± 1°C, equilibrated with 95% O~2~ and 5% CO~2~) and allowed 15 min to acclimate to the recording environment. The fEPSP in the CA1 was evoked by electrical stimulation. The stimulation electrode was positioned in Schaffer Collateral and the recording electrode (1--2 MΩ) was placed into the stratum radiatum of the CA1. The intensity of the electrical current (100--400 μ;A; 0.1--0.2 ms in duration) was set to the minimum amount of current required to generate ∼50% of the maximal initial slope (m~i~) of the fEPSP. The current stimulus used to examine the unpotentiated fEPSP was evoked at 700 μ;A (a stimulus intensity that evoked the maximal fEPSP amplitude in aCSF for all slices) and examined in aCSF, Mg^2+^-free aCSF, and Mg^2+^-free aCSF with 20 μ[m]{.smallcaps} AP5 (Sigma-Aldrich). The composition of Mg^2+^-free aCSF: 119.5 m[m]{.smallcaps} NaCl, 10 m[m]{.smallcaps} glucose, 20 m[m]{.smallcaps} sucrose, 25 m[m]{.smallcaps} NaHCO~3~, 3.0 m[m]{.smallcaps} KCl, 1.5 m[m]{.smallcaps} CaCl~2~, and 1.0 m[m]{.smallcaps} NaH~2~PO~4~. The NaCl was increased to 119.5 m[m]{.smallcaps} to keep osmolarity from changing when switching from aCSF to Mg^2+^-free aCSF. The fEPSP was evoked every 20 s. After 10 min of recording the baseline fEPSP, long-term potentiation (LTP) was induced using high-frequency stimulation (HFS) or theta burst stimulation (TBS). HFS consisted four 500-ms trains of stimuli (100 Hz) given at 30-s intervals. TBS consisted of four trains of 10 bursts at 5 Hz, each burst was comprised of four pulses at 100 Hz. The fEPSP slope was normalized to baseline values (before HFS).

All recordings were made using the Multiclamp 700B (Molecular Devices: <https://www.moleculardevices.com/systems/conventional-patch-clamp/multiclamp-700b-microelectrode-amplifier>). Acquisition and *post hoc* analyses were performed using the Axon pCLAMP10 software suite (Molecular Devices: <https://www.moleculardevices.com/system/axon-conventional-patch-clamp/pclamp-11-software-suite>).

Western blotting {#s3G}
----------------

Western blot assays were performed using entire hippocampal tissue homogenates from control and IH exposed mice. Hippocampal tissue from animals exposed to IH was harvested for Western blot analysis ∼12--16 h following the end of the IH~10~ protocol.

For quantitative analysis of HIF1a (R&D Systems catalog \#AF1935, RRID:[AB_355064](https://scicrunch.org/resolver/AB_355064)) and proliferating cell nuclear antigen (PCNA; Bethyl catalog \#A300-276A, RRID:[AB_263393](https://scicrunch.org/resolver/AB_263393)) content. Stepwise separation of cytoplasmic and nuclear protein extracts was prepared by NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific, 78833) by following manufacturer instructions. Briefly, cytoplasmic fragment was obtained by homogenizing tissue using a tissue grinder and then by pipetting in cytoplasmic extraction buffers. After isolation of cytoplasmic fragment, the insoluble pellet that contains nuclear proteins was suspended in nuclear extraction buffer and separated by centrifugation. Halt Protease Inhibitor (Thermo Scientific, 1860932) was added into cytoplasmic and nuclear extraction buffers to prevent protein degradation. Analyses for HIF1a and PCNA proteins were conducted by Raybiotech, using the automated capillary electrophoresis immunoassay machine (WES, ProteinSimple). The samples, blocking reagent, wash buffer, primary antibodies, secondary antibodies, and chemiluminescent substrate were dispensed into designated wells in the manufacturer provided microplate. After plate loading, the separation electrophoresis and immunodetection steps took place in the capillary system and were fully automated. Auto Western blot analysis was conducted at room temperature, and instrument default settings were used.

Quantitative Western blot analysis for GluN1, PSD-95, NADPH oxidase 4 (NOX4), and GAPDH were performed from hippocampal homogenates homogenized using either M-PER TM (Thermo Fisher Scientific) or RIPA buffer (Thermo Fisher Scientific) in the presence of protease and phosphatase inhibitors (Thermo Fisher Scientific) in cold ice. Samples were centrifuged at 14 rpm for 15 min at 4°C and the pellet was discarded. Samples were boiled for 15 min in loading buffer (Bio-Rad) at 60°C before loading 20- to 25-μ;g protein onto 4--20% Mini-PROTEAN TGX Stain-Free TM Protein Gels (Bio-Rad) and electrophoresed (120 V for 100 min) using Tris/glycine/SDS buffer (Bio-Rad). Gels were transferred to PVDF membrane (Bio-Rad) using Transfer-Blot Turbo System (Bio-Rad). Membranes were subsequently blocked (1 h, room temperature) with 5% non-fat milk (Bio-Rad) or 5% bovine serum albumin (BSA; Sigma-Aldrich) in Tris-buffered saline (Bio-Rad). Membranes were incubated (at 4°C overnight in 5% non-fat milk or BSA) under constant shaking with primary antibodies: monoclonal rabbit anti GluN1 (1:2000, Abcam), monoclonal rabbit anti-PSD-95 (1:1000, Cell signal), monoclonal rabbit anti- NOX4 (1:2000, Abcam), or monoclonal mouse anti-GAPDH (1:5000, Jackson ImmunoResearch). After washing three times with Tris-buffered saline-Tween 0.2% for 15 min, membranes were incubated (1 h, room temperature) with the appropriate secondary antibodies. Finally, membranes were washed three times with Tris-buffered saline-Tween 0.2% for 15 min, and immunoreactive proteins were detected with enhanced chemiluminescence (ECL) reagents according to manufacturer instructions (Bio-Rad). Signals were captured with the ChemiDoc system (Bio-Rad). The ImageJ image program (National Institutes of Health) was used to quantify optical band intensity.

Protein carbonyls {#s3H}
-----------------

Whole-cell protein lysates were isolated from hippocampal tissues by using M-PER mammalian protein extraction reagent (Thermo Scientific, 78501) and by adding Halt Protease Inhibitor (Thermo Scientific, 1860932). Protein lysates were immediately processed or kept in −80°C until used. The amount of protein carbonyls was determined using a Protein Carbonyl Colorimetric Assay kit (Cayman Chemical, catalog \#10005020), per manufacturer instructions and absorbance was measured at a wavelength between 360--385 nm using a plate reader. Protein content was determined using a Protein Determination kit (Cayman Chemical, catalog \#704002).

Experimental design and statistical analyses {#s3I}
--------------------------------------------

All n values are total number of animals, unless otherwise noted. Statistics were performed using Origin 8 Pro (OriginLab, RRID:[SCR_014212](https://scicrunch.org/resolver/SCR_014212)) or Prism 6 (GraphPad Software; RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)). Comparisons between two groups were conducted using unpaired two-tailed *t* tests with Welch's correction. To compare three or more groups, a one-way ANOVA was performed followed by *post hoc* Dunnett's test comparing experimental groups to control. Results are presented as single data points from each individual experiment and/or as the mean ± SEM. Significance was considered when *p* \< 0.05. See [Table 1](#T1){ref-type="table"} for statistical information related to analyses presented in this study.

###### 

Description of statistical tests and associated values used throughout the study

  Figure                                Statistical test                                      Statistical values
  ------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [1*A*](#F1){ref-type="fig"}           Unpaired *t* test with Welch\'s correction            *p* = 0.03; *t* = 2.789, df = 3
  [1*B*](#F1){ref-type="fig"}, left     One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.0044, *F* = 7.191, 1 vs 2 (training session): *p* \< 0.05, CI of diff = 23.74--217.9; 1 vs 3 (training session): *p* \< 0.01, CI of diff = 47.11--241.3
  [1*B*](#F1){ref-type="fig"}, right    One-way ANOVA, Dunnett\'s multiple comparison test.   One-way ANOVA *p* = 0.0006, *F* = 11.68, 1 vs 2 (training session): *p* \< 0.01, CI of diff = 63.81--239.3; 1 vs 3 (training session): *p* \< 0.001, CI of diff = 66.88--242.3
  [1*C*](#F1){ref-type="fig"}, left     Unpaired *t* test with Welch\'s correction            *p* = 0.04, *t* = 2.85, df = 9
  [1*C*](#F1){ref-type="fig"}, right    Unpaired *t* test with Welch\'s correction            *p* = 0.03, *t* = 2.501, df = 9
  [1*D*](#F1){ref-type="fig"}           Unpaired *t* test with Welch\'s correction            *p* = 0.0037; *t* = 3.436, df = 15
  [1*E*](#F1){ref-type="fig"}           Unpaired *t* test with Welch\'s correction            *p* = 0.84; *t* = 0.2118, df = 5
  [1*F*](#F1){ref-type="fig"}, left     One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.0136, *F* = 6.288, 1 vs 2 (training session): *p* \> 0.05, CI of diff = --12.74 to 207.3; 1 vs 3 (training session): *p* \< 0.01, CI of diff = 44.13--264.2
  [1*F*](#F1){ref-type="fig"}, right    One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.0156, *F* = 5.688, 1 vs 2 (training session): *p* \> 0.05, CI of diff = --3.202 to 221.3; 1 vs 3 (training session): *p* \< 0.05, CI of diff = 36.56--261.1
  [1*G*](#F1){ref-type="fig"}, left     Unpaired *t* test with Welch\'s correction            *p* = 0.547, *t* = 0.6258, df = 9
  [1*G*](#F1){ref-type="fig"}, right    Unpaired *t* test with Welch\'s correction            *p* = 0.48, *t* = 0.7431, df = 9
  [1*H*](#F1){ref-type="fig"}, left     Unpaired *t* test with Welch\'s correction            *p* = 0.2120, *t* = 1.356, df = 8
  [2*A*](#F2){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.0004, *F* = 10.20; control vs AP5: *p* \< 0.01, CI of diff = 21.28--62.13; control vs 10-IH: *p* \< 0.01, CI of diff = 5.21--44.71; control vs 10-IH+AP5: *p* \< 0.01, CI of diff = 11.04--51.89
  [2*B*](#F2){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* \< 0.0001, *F* = 116.9; control vs AP5: *p* \< 0.01, CI of diff = 54.80--80.72; control vs 10-IH: *p* \< 0.01, CI of diff = 56.41--82.32
  [2*C*](#F2){ref-type="fig"}           Unpaired *t* test with Welch's correction             *p* = 0.94; *t* = 0.065, df = 13.14
  [2*D*](#F2){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* \< 0.0001, *F* = 54.50; 0-HIF1a+/− vs 10-HIF1a+/−: *p* \> 0.05, CI of diff = --20.49 to 10.15; 10-HIF1a+/− vs 10-HIF1a+/−+ AP5: *p* \< 0.01, CI of diff = 42.75--75.42
  [3*B*](#F3){ref-type="fig"}, top      One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.56, *F* = 0.70; control vs IH~10~: *p* \> 0.05, CI of diff = --24.53 to 54.60; control vs 0-HIF1a+/−: *p* \> 0.05, CI of diff = --20.36 to 54.60; control vs 10-HIF1a+/−: *p* \> 0.05, CI of diff = --33.12 to 39.06
  [3*B*](#F3){ref-type="fig"}, bottom   One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.56, *F* = 0.70; control vs IH~10~: *p* \< 0.05, CI of diff = --70.53 to --6.241; control vs 0-HIF1a+/−: *p* \> 0.05, CI of diff = --56.75 to 3.840; control vs 10-HIF1a+/−: *p* \> 0.05, CI of diff = --40.38 to 17.97
  [3*C*](#F3){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.014, *F* = 4.74; control vs IH~10~: *p* \< 0.05, CI of diff = 0.96--0.78 ; control vs 0-HIF1a+/−: *p* \> 0.05, CI of diff = --0.38 to 0.05; control vs 10-HIF1a+/−: *p* \> 0.05, CI of diff = --0.27 to 0.157
  [3*D*](#F3){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.14, *F* = 2.39; control vs IH~10~: *p* \> 0.05, CI of diff = --0.42 to 0.27 ; control vs 0-HIF1a+/−: *p* \> 0.05, CI of diff = --0.63 to 0.0636; control vs 10-HIF1a+/−: *p* \> 0.05, CI of diff = --0.35 to 0.33
  [4*A*](#F4){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.006 *F* = 6.871, control vs IH~10~: *p* \< 0.01 CI of diff = --105.1 to --17.65; control vs 0-HIF1a+/−: *p* \> 0.05 CI of diff = --52.12 to 35.32; control vs 10-HIF1a+/−: *p* \> 0.05 CI of diff = --40.58 to 46.85
  [4*B*](#F4){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.003, *F* = 11.70; control vs IH~10~: *p* \> 0.05, CI of diff = --1.85 to --0.28; control vs 0-HIF1a+/−: *p* \> 0.05, CI of diff = --0.35 to 0.45; control vs 10-HIF1a+/−: *p* \> 0.05, CI of diff = --0.28 to 0.52
  [5*A*](#F5){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* = 0.0023, *F* = 10.00; control vs IH~10~: *p* \< 0.01, CI of diff = 0.09--0.75; control vs 10-MnTMPyP: *p* \> 0.05, CI of diff = --0.49 to 0.26
  [5*B*](#F5){ref-type="fig"}           One-way ANOVA, Dunnett\'s multiple comparison test    One-way ANOVA *p* \< 0.0001, *F* = 57.60, control vs IH: *p* \< 0.001, CI of diff = 50.58--88.15; control vs IH+MnTMPyP: *p* \> 0.05, CI of diff = --19.59 to 17.98
  [5*C*](#F5){ref-type="fig"}, top      One-way ANOVA, Dunnett's multiple comparison test     One-way ANOVA *p* = 0.0008, *F* = 6.32, 1 vs 2 (training session): *p* \> 0.05, CI of diff = --40.99 to 139.5; 1 vs 3 (training session): *p* \< 0.001, CI of diff = 71.59--252.1
  [5*C*](#F5){ref-type="fig"}, bottom   One-way ANOVA, Dunnett's multiple comparison test     One-way ANOVA *p* = 0.0056, *F* = 9.10, 1 vs 2 (training session): *p* \> 0.05, CI of diff = --25.40 to 187.3; 1 vs 3 (training session): *p* \< 0.01, CI of diff = 55.75--268.4
  [5*D*](#F5){ref-type="fig"}           Unpaired *t* test with Welch's correction             *p* = 0.0005; *t* = 4.292, df = 16.7112

Results {#s4}
=======

HIF1a protein content was measured in nuclear extracts prepared from wild-type mice unexposed to IH (control) and exposed to 10 d of IH (IH~10~). Nuclear HIF1a was approximately two times greater in extracts from IH~10~ than control (control *n* = 4, IH~10~ *n* = 4; [Fig. 1*A*](#F1){ref-type="fig"}). To determine the behavioral consequences of IH, we examined spatial learning and memory by assessing performance in a Barnes maze in control (*n* = 11) and IH~10~ (*n* = 10). During training, control and IH~10~ exhibited progressive improvement on locating the exit zone as indicated by the decrease in latency to exit over course of three training sessions and was similar between groups ([Fig. 1*B*](#F1){ref-type="fig"}).

![Ten days of IH increases hippocampal HIF1a and disrupts Barnes maze performance in wild-type mice but not in HIF1a+/−. ***A***, left, Representative digitized Western blotting images for HIF1a (103 kDa) and PCNA (40 kDa) in hippocampal nuclear protein fractions from control (*n* = 4) and IH~10~ (*n* = 4). Right, Quantification of HIF1a protein normalized to PCNA revealed that nuclear HIF1a was increased in IH~10~ when compared with control (*p* = 0.019). ***B***, Total latency to exit the Barnes maze during three training sessions in control (*n* = 10) and in IH~10~ (*n* = 11). Each blue (control) and red (IH~10~) line represents an individual performance during training. Training to the exit was conducted over three sessions. Each session was separated by 24 hours. ***C***, Left, During the probe trial, the distance traveled to initially enter the exit zone was shorter in control when compared with IH~10~ (*p* = 0.048). Right, Latency to initial entry was smaller in control as well (*p* = 0.034). ***D***, Heat maps of the mean entry probability across all false exits (1--19) and the exit zone during probe trial for the control and IH~10~. Comparison of entry probability into the exit zone during the probe trial reveals that control has a greater probability for entering the exit zone when compared with IH~10~ (*p* = 0.004). ***E***, Left, Representative digitized Western blotting images HIF1a and PCNA in hippocampal nuclear protein fractions from 0-HIF1a^+/−^ (*n* = 4) and 10-HIF1a^+/−^ (*n* = 4). Right, Quantification of HIF1a protein normalized to PCNA revealed that nuclear HIF1a is similar between 0-HIF1a^+/−^ and 10-HIF1a^+/−^ (*p* = 0.84). ***F***, Total latency to exit the Barnes maze during three training sessions in 0-HIF1a^+/−^ (*n* = 7) and in 10-HIF1a^+/−^ (*n* = 8). Each gray (0-HIF1a^+/−^) and yellow (10-HIF1a^+/−^) line represents an individual performance during training. All experimental groups exhibit decreased total latency over the course of training. ***G***, Left, In HIF1a^+/−^, the distance initial to initial entry into the exit zone was similar between 0-HIF1a^+/−^ and 10-HIF1a^+/−^ (*p* = 0.55). Right, Latency to initial entry into the exit zone during the probe trial were similar between 0-HIF1a^+/−^ and 10-HIF1a^+/−^ (*p* = 0.39). ***H***, Heat maps of the mean entry probability into all zones during the probe trial for 0-HIF1a^+/−^ and 10-HIF1a^+/−^. Entry probability was similar between 0-HIF1a^+/−^ and 10-HIF1a^+/−^ (*p* = 0.21); \**p* \< 0.05; \*\**p* \< 0.01; N.S., *p* \> 0.05.](SN-ENUJ200149F001){#F1}

In the probe trial (when the exit was closed), no difference was evident between the total distance traveled between control and IH~10~ (control: 25.22 ± 1.74 m vs IH~10~: 27.91 ± 2.21 m, *p* = 0.35; data not shown) suggesting no locomotor differences between groups. However, performance in locating the exit zone was different between control and IH~10~ as the distance to initial entry to the exit zone was greater in IH~10~ (control: 2.60 ± 0.70 m vs IH~10~: 10.34 ± 3.32 m, *p* = 0.048; [Fig. 1*C*](#F1){ref-type="fig"}), and a larger latency to initial entry exit zone was observed in IH~10~ (control: 22.60 ± 6.28 s vs IH~10~: 117.90 ± 37.47 s, *p* = 0.034;[Fig. 1*C*](#F1){ref-type="fig"}). Additionally, when comparing the probability to exit zone entry, the control group consistently discriminated the location of exit hole against the other holes, yet this was not apparent in IH~10~ (control: 15.93 ± 2.39% vs IH~10~: 6.44 ± 1.38%, *p* = 0.0037;[Fig. 1*D*](#F1){ref-type="fig"}). Together, these findings indicated that wild-type animals exposed to IH have increased expression of HIF1a and impairments to spatial memory.

Nuclear HIF1a protein content was similar between extracts from hippocampi of HIF1a^+/−^ mice unexposed to IH (0-HIF1a^+/−^) when compared with HIF1a^+/−^ mice exposed to 10 d of IH (10-HIF1a^+/−^; 0-HIF1a^+/−^, *n* = 4, 10-HIF1a^+/−^ *n* = 4;[Fig. 1*E*](#F1){ref-type="fig"}). In 0-HIF1a^+/−^ (*n* = 7), and 10-HIF1a^+/−^ (*n* = 8) performance in the Barnes maze was similar over the course of the training sessions ([Fig. 1*F*](#F1){ref-type="fig"}). During the probe trial, the total distance traveled by 0-HIF1a^+/−^ to 10-HIF1a^+/−^ were similar (0-HIF1a^+/−^ = 19.47 ± 1.61 m, 10-HIF1a^+/−^ = 22.42 ± 1.61 m; *p* = 0.55; data not shown) suggesting no locomotor differences between groups. Moreover, the distance to initial entry to the exit zone (0-HIF1a^+/−^ = 2.37 ± 0.91 m, 10-HIF1a^+/−^ = 1.71 ± 0.50 m; *p* = 0.54; [Fig. 1*G*](#F1){ref-type="fig"}), latency to initial entry into the exit zone (0-HIF1a^+/−^ = 35.18 ± 12.28 s, 10-HIF1a^+/−^ = 57.28 ± 27.08 s; *p* = 0.48;[Fig. 1*G*](#F1){ref-type="fig"}); and the entry probability into the exit zone (0-HIF1a^+/−^ = 8.75 ± 1.38%, 10-HIF1a^+/−^ = 15.51 ± 4.73%; *p* = 0.21;[Fig. 1*H*](#F1){ref-type="fig"}) for 0-HIF1a^+/−^ and 10-HIF1a^+/−^ were similar between both groups. These data demonstrate that in HIF1a^+/−^ mice the IH-dependent increase in nuclear HIF1a protein was mitigated, and spatial memory was unaffected by IH. Furthermore, these data raise the possibility that increased hippocampal nuclear HIF1a signaling causes deficits to hippocampal LTP.

The mechanisms underlying LTP are key substrates for learning and memory. We, therefore, examined LTP from area CA1 in hippocampal in brain slices from control and IH~10~. LTP from control was consistently evoked by HFS (LTP~HFS~; [Fig. 2*A*](#F2){ref-type="fig"}, blue, *n* = 6). NMDAr blockade with AP5 attenuated LTP~HFS~ magnitude but did not prevent the occurrence of the phenomenon ([Fig. 2*A*](#F2){ref-type="fig"}, green, *n* = 5). These findings demonstrated that both NMDAr-dependent and NMDAr-independent mechanisms contributed to the generation of LTP~HFS~. Following IH, LTP~HFS~ was smaller in magnitude ([Fig. 2*A*](#F2){ref-type="fig"}, red, *n* = 6) and was no longer sensitive to AP5 ([Fig. 2*A*](#F2){ref-type="fig"}, gold, *n* = 5).

![IH suppresses NMDAr-dependent synaptic potentiation in wild-type hippocampal slices, but NMDAr-dependent LTP is unaffected by IH in the hippocampal slices from HIF1a^+/−^. ***A***, LTP was evoked using HFS in control (blue, *n* = 6) is attenuated by AP5 (green, *n* = 5). LTP~HFS~ is attenuated in following IH (IH~10~, red, *n* = 6) and is no longer sensitive to AP5 (IH+AP5, gold, *n* = 5). A comparison of LTP~HFS~ magnitude (60 min following HFS) was performed to compare experimental conditions to control; \*\**p* \< 0.01. ***B***, LTP~TBS~ is readily evoked in control (light blue, *n* = 5) and is completely blocked by AP5 (light green, *n* = 5). Following IH, LTP~TBS~ is present (IH~10~, pink, *n* = 5). Following a one-way ANOVA, a *post hoc* comparison of LTP~TBS~ magnitude (60 min following TBS) was performed to compare experimental conditions to control; \*\*\**p* \< 0.01. ***C***, LTP~HFS~ was evoked in both 0-HIF1a^+/−^ (*n* = 8, gray) and 10-HIF1a^+/−^ (*n* = 8, dark yellow). No difference was found when comparing LTP~HFS~ magnitude between 0-HIF1a^+/−^ and 10-HIF1a^+/−^ (*p* = 0.94). ***D***, LTP~TBS~ was evoked in both 0-HIF1a^+/−^ (*n* = 6, light gray), 10-HIF1a^+/−^ (*n* = 5, light yellow), and 10-HIF1a^+/−^ + AP5 (*n* = 5, light green). No difference was found when comparing LTP~TBS~ magnitude of 0-HIF1a^+/−^ and 10-HIF1a^+/−^. Representative traces illustrate baseline (black) and 60 min following HFS (colored trace). Scale bars: 0.2 mV/10 ms. In experiments using AP5, electrophysiological recordings began at 20 min before eliciting LTP (i.e., *t* = −20) while AP5 was applied 10 before eliciting LTP (i.e., *t* = −10). For all the experiment, the arrow represents the electric protocols: HFS or TBS; \*\*\**p* \< 0.001, \*\**p* \< 0.01; N.S., *p* \> 0.05.](SN-ENUJ200149F002){#F2}

We next examined whether IH prevented another LTP evoked by TBS (LTP~TBS~; [Fig. 2*B*](#F2){ref-type="fig"}, light blue, *n* = 5), a form of synaptic potentiation dependent on the NMDAr, as AP5 prevent LTP~TBS~ ([Fig. 2*B*](#F2){ref-type="fig"}, light green, *n* = 5). Following IH, LTP~TBS~ could no longer be evoked ([Fig. 2*B*](#F2){ref-type="fig"}, pink, *n* = 5).

In contrast to the wild type, LTP~HFS~ was similar in 0-HIF1a^+/−^ ([Fig. 2*C*](#F2){ref-type="fig"}, gray *n* = 8) and in 10-HIF1a^+/−^ ([Fig. 2*C*](#F2){ref-type="fig"}, dark yellow, *n* = 8). In the hippocampal brain slice, the magnitude of LTP~TBS~ was similar between 0-HIF1a^+/−^ ([Fig. 2*D*](#F2){ref-type="fig"}, light gray, *n* = 6) and in 10-HIF1a^+/−^ ([Fig. 2*D*](#F2){ref-type="fig"}, light yellow, *n* = 5). Additionally, AP5 blocked LTP~TBS~ in the 10-HIF1a^+/−^ ([Fig. 2*D*](#F2){ref-type="fig"}, light green, *n* = 4). Together, these findings suggested that IH-dependent HIF1a signaling suppresses NMDAr-dependent potentiation by disrupting the NMDAr physiology. To test this, we examined the contribution of the NMDAr to the unpotentiated fEPSP.

A fEPSP with maximal amplitude in aCSF (fEPSP~max~) was evoked using saturating current stimulus (700 μA; [Fig. 3*A*](#F3){ref-type="fig"}, black, aCSF) in control (*n* = 6, fEPSP~max~= −1.05 ± 0.14 mV), IH~10~ (*n* = 7, fEPSP~max~= −0.85 ± 0.08 mV), 0-HIF1a^+/−^ (*n* = 9, fEPSP~max~= −0.941 ± 0.04 mV), and 10-HIF1a^+/−^ (*n* = 11, fEPSP~max~= −0.90 ± 0.06 mV). When compared with control, no difference in fEPSP~max~ was observed from any experimental group (one-way ANOVA: *p* = 0.39, *F* = 1.035; control vs IH~10~: *p* \> 0.05, 95% CI of diff = −0.4960 to 0.09,542; control vs 0-HIF1a^+/−^: *p* \> 0.05, 95% CI of diff = −0.3938 to 0.1665; 10-HIF1a^+/−^: *p* \> 0.05, 95% CI of diff = −0.4219 to 0.1176; data not shown). Switching to Mg^2+^-free aCSF relieved the Mg^2+^ blockade of existing NMDAr and caused the fEPSP to increase all groups ([Fig. 3*A*](#F3){ref-type="fig"}, blue, Mg^2+^ free). The change in fEPSP amplitude from aCSF to Mg^2+^ free was not different when comparing the other experimental groups to control ([Fig. 3*B*](#F3){ref-type="fig"}, top). However, the NMDAr antagonist, AP5, reduced the fEPSP in 0-HIF1a^+/−^ and 10-HIF1a^+/−^ similar to that of control ([Fig. 3*A*](#F3){ref-type="fig"}, red, AP5) yet was less effective in IH~10~ ([Fig. 3*B*](#F3){ref-type="fig"}, bottom). These findings suggested that IH suppressed contribution of the conductance of NMDAr within neurons in a HIF1a dependent manner. Such an effect could be due to direct effects on unitary conductance of the NMDAr or by the down regulation of the receptor itself. Therefore, we examined whether expression of the GluN1, the obligatory subunit of the NMDAr, was disrupted by IH.

![The IH reduces the contribution of the NMDAr to fEPSP and GluN1 protein from wild-type mice but does not induce these changes in HIF1a^+/−^. ***A***, Representative traces of the fEPSP from control, IH~10~, 0-HIF1a^+/−^, and 10-HIF1a^+/−^ in: aCSF (black), Mg^2+^-free media (blue), and Mg^2+^-free media with AP5 (red). Scale bars: 0.4 mV/10 ms. ***B***, top, Change in amplitude of the fEPSP from aCSF to Mg^2+^-free media. Bottom, Change in amplitude of the fEPSP from Mg^2+^-free media to Mg^2+^-free media with AP5; \**p* \< 0.05; N.S., *p* \> 0.05. ***C***, left, Representative Western blottings of GluN1 and the housekeeping protein, GAPDH from control (*n* = 5), IH~10~ (*n* = 5), 0-HIF1a^+/−^ (*n* = 5), and 10-HIF1a^+/−^ (*n* = 5). Right, Comparisons of normalized GluN1 protein expression were performed to compare experimental conditions to control. This revealed that GluN1 was reduced in IH~10~ and unchanged in both 0-HIF1a^+/−^ and 10-HIF1a^+/−^; \**p* \< 0.05; N.S., *p* \> 0.05. ***D***, left, Representative Western blottings of PSD-95 and the housekeeping protein, GAPDH from control (*n* = 3), IH~10~ (*n* = 3), 0-HIF1a^+/−^ (*n* = 3), and 10-HIF1a^+/−^ (*n* = 3). Right, Comparisons of normalized PSD-95 protein expression were performed to compare experimental conditions to control; \**p* \< 0.05; N.S., *p* \> 0.05.](SN-ENUJ200149F003){#F3}

We compared GluN1 subunit expression in control (*n* = 5), IH~10~ (*n* = 5), 0-HIF1a^+/−^ (*n* = 5), and 10-HIF1a^+/−^ (*n* = 5). IH reduced GluN1 in wild-type hippocampi, yet GluN1 expression was similar to control in both 0-HIF1a^+/−^ or 10-HIF1a^+/−^ ([Fig. 3*C*](#F3){ref-type="fig"}). This reduction in GluN1 may have resulted from an IH-mediated reduction in synapse. Therefore, we sought to determine whether IH caused a reduction in a scaffolding protein of the glutamatergic synapse PSD-95 ([Fig. 3*D*](#F3){ref-type="fig"}, *n* = 3 per group). When compared with control, no difference in PSD-95 was detected any experimental group ([Fig. 3*D*](#F3){ref-type="fig"}). These findings together indicated that IH-dependent HIF1a signaling specifically likely targets a reduction of the NMDAr by suppressing GluN1 expression without causing gross reductions in glutamatergic synapses. Such a reduction in NMDAr expression would likely contribute to the reduced sensitivity to AP5 following IH and contribute to impaired NMDAr-dependent LTP.

As IH-dependent HIF1a signaling can lead to a pro-oxidant condition, we next sought to determine whether IH-dependent HIF1a signaling enhanced ROS production within the hippocampus. Protein carbonyl content in hippocampal homogenates from control (*n* = 4), IH~10~ (*n* = 4), 0-HIF1a^+/−^ (*n* = 4), and 10-HIF1a^+/−^ (*n* = 4) revealed that protein carbonyl content was elevated in IH~10~ yet unchanged changed in homogenates from either 0-HIF1a^+/−^ or 10-HIF1a^+/−^ ([Fig. 4*A*](#F4){ref-type="fig"}). NOX4 is a ROS generating protein that can be transcriptionally regulated by HIF1a ([@B9]). Therefore, we next determined Nox4 expression in hippocampal homogenates from control (*n* = 5), IH~10~ (*n* = 5), 0-HIF1a^+/−^ (*n* = 5), and 10-HIF1a^+/−^ (*n* = 5). NOX4 was elevated in IH~10~ yet unchanged changed in homogenates from either 0-HIF1a^+/−^ or 10-HIF1a^+/−^ ([Fig. 4*B*](#F4){ref-type="fig"}). Together, these data suggest that enhanced ROS production by IH-dependent HIF1a signaling involves the upregulation of NOX4. However, IH-dependent ROS production was involved with the changed expression of GluN1 remained uncertain.

![IH enhances protein carbonyl content and increase NOX4 expression in wild type but not in HIF1a^+/−^. ***A***, Hippocampal homogenates from control (*n* = 4), IH~10~ (*n* = 4), 0-HIF1a^+/−^ (*n* = 4), and 10-HIF1a^+/−^ (*n* = 4). While IH~10~ displayed elevated protein, carbonyl content was not elevated in either 0-HIF1a^+/−^ or 10-HIF1a^+/−^. ***B***, Comparison of the pro-oxidant enzyme, NOX4, from control (*n* = 5), IH~10~ (*n* = 5), 0-HIF1a^+/−^ (*n* = 5), and 10-HIF1a^+/−^ (*n* = 5) reveals that NOX4 is increased in IH~10~; *p* \< 0.01), but not elevated in either 0-HIF1a^+/−^ or 10-HIF1a^+/−^; \*\**p* \< 0.01; N.S., *p* \> 0.05.](SN-ENUJ200149F004){#F4}

To resolve the involvement of IH-dependent ROS production on the regulation of GluN1, protein homogenates were prepared from four groups: control (*n* = 4); IH~10~ (*n* = 4); wild-type mice administered saline during 10 d of IH exposure (IH~Saline~, *n* = 4); wild-type mice administered the superoxide anion scavenger, MnTMPyP, during IH (IH~MnTMPyP~, *n* = 4). GluN1 was reduced in IH~10~ and IH~Saline~; however, GluN1 from 10-MnTMPyP was similar to that of control ([Fig. 5*A*](#F5){ref-type="fig"}), which coincided with the ability to evoke LTP~TBS~ from IH~MnTMPyP~ (*n* = 5; [Fig. 5*B*](#F5){ref-type="fig"}). Behavioral performance was also assessed in IH~Saline~ (*n* = 11) and IH~MnTMPyP~ (*n* = 10). Both IH~Saline~ and IH~MnTMPyP~ exhibited a progressive improvement in locating the exit as indicated by the total latency to exit over the course of training ([Fig. 5*C*](#F5){ref-type="fig"}). During the probe trail, the two groups exhibited similar values for distance to initial entry into the exit zone (IH~Saline~ = 0.29 ± 0.06 m, IH~MnTMPyP~ = 0.28 ± 0.05 m; *p* = 0.87; data not shown), and similar latency to initial entry into the exit zone (IH~Saline~ = 77.74 ± 24.42 s, IH~MnTMPyP~ = 26.00 ± 5.67 s; *p* = 0.06; data not shown), although the variance between the values for latency to initial entry was different between IH~Saline~ and IH~MnTMPyP~ (*F* = 17.00, DFn = 10, Dfd = 11; *p* \< 0.0001; data not shown). Moreover, entry probability into the exit zone during the probe trial was greater in IH~MnTMPyP~ (IH~Saline~ = 4.33 ± 0.63%, IH~MnTMPyP~ = 10.32 ± 1.26%; *p* = 0.0005; [Fig. 5*D*](#F5){ref-type="fig"}). These data indicated that scavenging IH-derived superoxide anion prevented the reduction in the obligatory subunit of the NMDAr, prevented the loss of LTP~TBS~, and mitigated behavioral deficits caused by IH.

![Antioxidant treatment mitigates the IH-dependent effects on GluN1 expression, LTP~TBS,~ and performance in the Barnes maze. ***A***, left, Representative Western blottings of GluN1 and GAPDH from Control, IH~10~, wild-type mice treated with saline during 10 d of IH (i.e., vehicle control exposed to IH, IH~Saline~, *n* = 4), wild-type mice treated with MnTMPyP during 10 d of IH (IH~MnTMPyP~). Right, Normalized GluN1 protein expression was examined in control (*n* = 4), IH~10~ (*n* = 4), IH~Saline~ (*n* = 4), IH~MnTMPyP~ (*n* = 4). No difference in GluN1 was evident between IH~10~ (open black circles in IH~10~ label) and IH~Saline~ (open blue circles in IH~10~ label); therefore, the two groups were merged into the IH~10~ label for comparisons to control. Comparisons revealed that GluN1 was reduced only in IH~10~ and unchanged in IH~MnTMPyP~. ***B***, In hippocampal slices from IH~MnTMPyP~, LTP~TBS~ (*n* = 5) could be reliably evoked contrasting the effect of IH~10~ on LTP~TBS~ ([Fig. 2*B*](#F2){ref-type="fig"}). Scale bars: 0.2 mV/10 ms. The arrow represents the TBS protocol. ***C***, The total latency to exit the Barnes maze progressively decreased in both IH~Saline~ (*n* = 11, pink lines represent individual performance) and IH~MnTMPyP~ (*n* = 10, purple lines represent individual performance), suggesting that both groups could learn the exit zone location. ***D***, Heat maps of the mean entry probability across all false exits (1--19) and the exit zone during the probe trial for IH~Saline~ and IH~MnTMPyP~. Comparison of entry probability into the exit zone during the probe trial reveals that IH~MnTMPyP~ has a greater probability for entering the exit zone when compared with IH~Saline~ (*p* = 0.006); \*\*\**p* \< 0.001, \**p* \< 0.05; N.S., *p* \> 0.05.](SN-ENUJ200149F005){#F5}

Discussion {#s5}
==========

Our study establishes a role for IH-dependent HIF1a signaling in impairing hippocampal neurophysiology that supports spatial memory. Consistent with previous reports indicating that IH impacts spatial memory ([@B28]; [@B14]), we observed that IH disrupted performance in the Barnes maze. The cognitive disruptions we observed coincided with enhanced nuclear HIF1a in the hippocampus, a shift toward a pro-oxidant state, and impairment to NMDAr-dependent LTP. We found that either heterozygosity in HIF1a and antioxidant administration prevented the effects of IH on the hippocampus. Together, these findings reveal a mechanistic pathway by which IH such as that experienced with sleep apnea impairs mechanisms underpinning spatial memory.

Evaluating the behavioral performance in control and IH~10~ showed that both groups progressively improved with training, yet prominent differences were present during the probe trial. These results suggested IH produced modest impairments to cognitive performance and is reminiscent of mild cognitive deficits documented among individuals suffering from sleep apnea ([@B34]; [@B8]; [@B19]). These behavioral impairments coincided with targeted loss in NMDAr-dependent LTP after IH. However, neither the behavioral deficits nor impaired synaptic potentiation was observed in HIF1a^+/−^ exposed to IH implicating a role for IH-dependent HIF1a signaling in these phenomena.

Although administration of the prolyl hydroxylase inhibitor, dimethyloxalylglycine (DMOG), enhances HIF1a and coincides with the suppression of hippocampal LTP ([@B33]), this pharmacological approach for enhancing HIF1a can also disrupt cellular respiration well before the activation of HIF1a-dependent pathways ([@B38]). This confounds understanding how enhanced HIF1a may impact hippocampal synaptic plasticity. Our experiments using HIF1a^+/−^ mice resolved this issue. Heterozygosity in HIF1a prevented the IH-dependent increase in NOX4, the ROS-producing enzyme transcriptionally regulated by HIF1a ([@B9]). Increasing NOX4 would be expected to increase the production of ROS and, if left unchecked, promote a pro-oxidant state. Indeed, IH led to increased protein carbonylation, an indication of a shift toward a more pro-oxidant state. The HIF1a-dependent increase in pro-oxidant condition was presumably due to ROS production from the enhanced presence of NOX4. The pro-oxidant state suppressed NMDAr-dependent LTP and disrupted performance in the Barnes maze.

In agreement with a previous report ([@B13]), our protein analyses indicated that IH reduced GluN1 expression, the obligatory subunit of the NMDAr. Alone, this observation could not discriminate whether the effect of IH on GluN1 expression reflected a reduction of the NMDAr at the glutamatergic synapse, a decline in extrasynaptic receptors, a premature degradation of GluN1 before assembly of the receptor or some combination of the three. The reduction in GluN1 was not accompanied by a reduction in PSD-95, suggesting that IH did not indiscriminately cause a loss of glutamatergic synapses. Following IH, the unpotentiated fEPSP (in Mg^2+^-free aCSF) was less sensitive to NMDAr blockade. Together, these findings may be interpreted as indicating that IH remodels the glutamatergic synapse by reducing receptor expression. Such a reduction in the synaptic NMDAr would likely disrupt NMDAr-dependent LTP. However, this may not be the only avenue by which IH disturbs NMDAr-based physiology.

Administration of MnTMPyP during IH prevented both GluN1 reduction and impairment to NMDAr-dependent LTP. Similarly, in 10-HIF1a^+/−^, GluN1 expression and NMDAr-dependent LTP was similar to that of control. These findings together indicate that HIF1a mediated ROS production is a principal mechanism that diminishes NMDAr function. While our experiments support the possibility that IH causes reduced receptor expression, the conductance of the NMDAr is known to be redox sensitive ([@B1]; [@B18]). Specifically, oxidation of the NMDAr attenuates NMDAr conductance ([@B4]; [@B20]; [@B15]; [@B10]). It is, therefore, likely that some combination of oxidative modulation and downregulation of the NMDAr mediates the disrupted NMDAr physiology caused by IH. However, we did not acutely manipulate redox state and do not know to what extent the two processes contribute IH-dependent effects on NMDAr activity. This remains an open question to be investigated.

Independent of the precise cause, changed NMDAr activity by IH likely decreases the NMDAr-dependent rise in intracellular Ca^2+^. While a rise intracellular Ca^2+^ is an important event for downstream intracellular signaling critical to LTP, it also is likely to mediate other Ca^2+^-dependent processes within the neuron. With respect to IH, ROS production can increase intracellular Ca^2+^ via the inositol 1,4,5-trisphosphate receptor (IP3R; [@B36]), which then serves as a positive feedback mechanism to enhance and stabilize HIF1a signaling ([@B26]). As we observed that IH increases NOX4 and protein carbonyls in a HIF1a dependent fashion, excess elevations in intracellular Ca^2+^ within hippocampal cells may promote a feedforward mechanism that enhances HIF1a activity and ROS generation. Thus, the reduction of NMDAr activity may serve as a necessary phenomenon to minimize intracellular Ca^2+^ and prevent potential exacerbation of cellular stress if left unregulated.

The forced shift from NMDAr-dependent to NMDAr-independent forms of synaptic plasticity observed with IH is a phenomenon also found in models of the aging ([@B2]; [@B27]). Thus, IH, like normal aging, limits the mechanisms normally used to support learning and memory in younger animals. Our work indicates that the HIF1a dependent pro-oxidant condition causes this aging phenotype. As the current study used younger animals (P50--P80), examining how IH affects mechanisms of learning and memory in aged subjects will be important to resolve.

In conclusion, we have identified an important pathway by which IH-dependent HIF1a signaling causes a pro-oxidant state that destabilizes hippocampal synaptic plasticity and disrupts spatial memory. We propose that these observations establish a mechanistic framework by which sleep apnea may lower of the threshold for cognitive impairment ([Fig. 6](#F6){ref-type="fig"}). This mechanism may contribute to the emergence of neurologic diseases associated with untreated sleep apnea.

![A mechanistic framework by which sleep apnea lowers the threshold for cognitive impairment. Schematic synthesizing our findings into a pathway by which IH promotes a pro-oxidant state in the hippocampus that impairs NMDAr-dependent plasticity and spatial memory.](SN-ENUJ200149F006){#F6}
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Reviewing Editor: Bradley Postle, University of Wisconsin

Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: Thomas Foster, Ashok Kumar.

Here is the full text of the reviews:

R1:

The authors did a nice job and have a fairly complete story. Below are suggestions to improve the manuscript. Major concerns relate to needed comparisons between WT and Hif1a+/- mice. In addition, I have concerns about the proposed link between impaired LTP, NMDAr function, and NMDAr expression.

Methods

For measures of nuclear Hif1a, when was the tissue harvested relative to treatment?

Barnes Maze began on the seventh day of IH10 exposure with respective controls run at the same time. Was the testing performed immediately after the treatment on day 7?

Define primary latency to exit zone versus initial latency.

Results

Is there a behavioral difference in WT and Hif1a+/-? It appears there may be a difference in learning for the controls (Fig 1c vs Fig1f).

One assumption is that the LTP in Hif1a+/- mice is due to NMDAr; however, this was not shown (i.e. include AP5). This data needs to be included.

It is difficult to measure decay time of NMDAr synaptic responses in extracellular recording and there are several problems in the current study.

1\) One problem is the peak amplitudes are vastly different before and after application of AP5 in control mice. Was there a difference in the input/output relationship (AMPAr or NMDAr) between control and Hif1a+/- mice? Was there a difference in input/output curves before and after AP5? At the very least, was there a difference in the maximally evoked fEPSP across mouse strains or due to AP5 application? It appears that AP5 results in a large decrease in the amplitude for the WT control slices (Fig3A). This is not observed for IH10 or Hif1a+/- mice, which suggests fewer NMDARs are at the synapse following IH in WT mice and that synaptic NMDAr levels are low in Hif1a+/- mice regardless of treatment. The question of amplitude differences is also important for interpretation of western blot studies of subunit expression and possible synaptic loss (see Discussion comments).

2\) Second, in order to measure the true decay, the responses should be normalized to the peak (i.e. peak = 100%). Thus, the peaks in each panel should lineup on the horizontal plane and decay differences would then be evident. In figure 3, the decay is contaminated by differences in the peak.

Discussion

Missing from the discussion is the mechanism for the decrease in LTP and apparent decrease in the NMADr response. The authors state: our findings indicate that IH reduces receptor expression causing targeted loss of NMDAr-dependent LTP through a HIF1a mediated pro-oxidant mechanism. Implicit in this statement is the assumption that the decrease in LTP is due to a decrease in NMDAr at the synapse.

First, the authors should discuss whether the reduction in NMDAr expression represents synapse loss, a decreased level of NMDAr at the synapse in the absence of synaptic loss, or loss from intracellular or extrasynaptic compartments. In this case, input/output curves of the fEPSP would help. If the AMPAr component of transmission is not altered, this would suggest no loss of synapses, but does not rule out redox state changes in NMDAr function. If the input/output curve was also decreased, it is possible that there is synaptic loss. In addition, it would have been helpful if the authors had a measure of synaptic number (e.g. PSD95 western blots).

Second, the authors did not test for a decrease in NMDAr function due to redox state as reported by the Lipton and Foster groups. In this case, the authors would have needed to determine the effects of oxidizing or reducing agents. Thus, this possibility cannot be ruled out.

Editorial

For figure 1c, distance should be distance to initial entry.

Can the authors supply a better western blot figure 3C? The way the gel ran and the lane difference make it appear as if GluN1 and GAPDH are from different gels.

Concerning the possibility that IH is acting on unitary conductance of the NMDAr or down regulating the receptor. The authors state: This possibility would not be resolved through further electrophysiological investigation alone. This sentence should be removed or modified. The possibility could be resolved with patch-clamp electrophysiological studies.

These findings indicated that IH-dependent HIF1a signaling suppresses NMDAr expression within the hippocampus, that would contribute to a reduction of NMDAr conductance within individual CA1 neurons. Change to . . . hippocampus, which could . . . The word change, from would to could, is needed since it is not clear that the NMDAr expression represents synaptic receptors.

R2:

This study examines the mechanisms and the role of the transcription factor, hypoxia-inducible factor 1a (HIF1a), in cognitive and synaptic function impairment caused by sleep apnea. The rationale is that sleep apnea induces intermittent hypoxia, which is a major mediator of pathophysiology including decline in cognitive and synaptic function. Here, the authors therefore use the Barnes maze that examines hippocampal-dependent spatial memory, brain slice electrophysiology to measure synaptic plasticity in wild type and heterozygous Hif1a mice exposed to intermittent hypoxia and treated with antioxidant, MnTMPyP. In wild type mice, intermittent hypoxia-induced impaired spatial memory was associated with a decline in NMDA receptor dependent LTP and an increase in nuclear factor HIF1a within hippocampus. Intermittent hypoxia-induced HIF1a signaling was also associated with augmented expression of NADPH oxidase 4 and downregulation of GluN1 expression. The intermittent hypoxia-induced effects and HIF1a signaling were not observed in heterozygous for Hif1a or wild type mice treated with MnTMPyP.

The behavioral and physiological results are interesting and the data are surely novel and make a significant contribution. Suggestions for clarification and improvement.

I would raise the point that of the relationship between the title and the content of the manuscript. The title reads "A HIF1a-dependent pro-oxidant state disrupts synaptic plasticity and impairs spatial memory in a model of sleep apnea" and I was building up to it, to this idea of that "sleep apnea will be induced in these animals at some point before behavioral, synaptic, and other measurements. However, I do not think sleep apnea was induced, rather animals were exposed to intermittent hypoxia, and inclusion of heterozygous Hif1a and treatment with antioxidant. I would suggest a change in the title of the manuscript, something like "A HIF1a-dependent pro-oxidant state disrupts synaptic plasticity and impairs spatial memory in mice". If the authors thinks that heterozygous Hif1a mouse is a model of sleep apnea. In that case, please provide a discussion in the introduction/methods.

I am very enthusiastic for the authors to use P50 to P80 mice for delineating the role of HiF1a signaling in intermittent hypoxia induced-alterations in spatial memory and synaptic plasticity. Considering that, these are very young animals and might be passing just through their developing stage (P50), I am wondering how these findings will be interpreted in relation to adult animals. However, if for whatever reasons of available time/availability of adult animals/commitments, and you are not in a position currently to employ advanced age animals, then I would suggest please provide a short discussion in that perspective.

NMDA receptor is a heterotetramer, consisting of GluN1, an obligatory subunit and GluN2A-D subunit as optional ones. In my opinion, inclusion of expression profile of GluN2A/GluN2B in the current study will definitely make it more interesting and overall status of subunit expression profile during intermittent hypoxia.

Minor points

1\) Expand and abbreviate NMDAr (line 43), N-methyl-D-aspartate receptor (NMDAr).

2\) Abbreviate "the field excitatory postsynaptic potential" at first use (fEPSP) (line 97).

3\) Expand PCNA at first use (line 119), Proliferating Cell Nuclear Antigen.

4\) Expand and abbreviate long-term potentiation (LTP) at first use (line 109).

5\) Delete "changed" from "protein carbonyl content was elevated in IH10 yet unchanged changed in homogenates" (line 231).

6\) Same at line 236, "elevated in IH10 yet unchanged changed in homogenates from either 0-HIF1a+/- or 10-HIF1a+/\"

7\) Expand and abbreviate DMOG at first use (line 271) in case you are using the same again, Dimethyloxalylglycine (DMOG).

8\) Be consistent with the use of MnTMPyP, in line 286, it is written MnTMyPyP.

9\) Add an arrow for HFS/TBS, indicating start of stimulation paradigm for induction of LTP, in figure 2.

10\) Both side of hippocampi from a mouse were included for Western blot and carbonyl protein analysis or hippocampus was isolated into ventral hippocampus, CA3, CA1, and DG, and region-specific tissues were pooled together? Please provide details in method section.

11\) Change reactive oxygen species to ROS (line 277).

12\) It might be worth including citations by Bodhinathan et al, 2010, Journal of Neuroscience; Haxaire et al 2012, Aging Cell; Kumar and Foster 2013, Journal of Neuroscience, which would enhance the author's point that modulation of oxidative state can influence NMDA receptor synaptic function and spatial memory (line 287).

13\) Please use expanded version of IP-3 receptor at first use, Inositol 1,4,5-trisphosphate (IP3) receptor (line 292).

14\) Editorials, "approach to enhancing HIF1a" approach to enhance (line 272); "by which sleep apnea may lower of the threshold for cognitive impairment\", delete of (line 301-2)?

Author Response {#s7}
===============

We would like to thank both of the reviewers for their thoughtful input. Based on their specific comments, we added additional experiments revised the manuscript, which has improved the manuscript. Our response to specific issues raised are described below.

R1:

The authors did a nice job and have a fairly complete story. Below are suggestions to improve the manuscript. Major concerns relate to needed comparisons between WT and Hif1a+/- mice. In addition, I have concerns about the proposed link between impaired LTP, NMDAr function, and NMDAr expression.

Our Response: We would like to thank Reviewer 1 for the assessment of our study. Our detailed response to the specific issues raised are stated below.

Methods

For measures of nuclear Hif1a, when was the tissue harvested relative to treatment?

Our Response: Tissue for HIF1a, NOX4, and NR1 was harvested approximately 12 to 16 hours following the ending of the IH protocol on the tenth day of exposure. We have revised the manuscript to reflect this, see lines 163 to 165.

Barnes Maze began on the seventh day of IH10 exposure with respective controls run at the same time. Was the testing performed immediately after the treatment on day 7?

Our Response: The Barnes maze protocol was started prior to the beginning of IH exposure. Barnes Maze began on the seventh day of IH10 exposure with respective controls run at the same time. In IH mice, all training trials and the probe trial were conducted prior to IH exposure on days 7 to 10. We have revised the manuscript to reflect this, see lines 113 to 115.

Define primary latency to exit zone versus initial latency. Is there a behavioral difference in WT and Hif1a+/-? It appears there may be a difference in learning for the controls (Fig 1c vs Fig1f).

Our Response: We apologize for the confusion. Primary latency and latency to initial entry are synonymous in meaning. To reduce confusion, we have revised the text and replaced primary latency with latency to initial entry. Total latency used in training was defined as the elapsed time from the start of the trial to when subject entered the exit. If the mouse was unable to locate the exit by six minutes, they were gently guided to the exit and total latency for the trial was reported as 360 sec.

During the first training trial, many of the mice from 0-HIF1a+/- needed to be guided to the exit or had a very large total latency. However, by the end of third training trial, the group exhibited evidence for learning the location of the exit, as evidenced by the smaller total latency values.

Both distance and latency to initial entry into the exit zone were similar to control (Fig1C. vs. Fig1G). There may have been some confusion when comparing entry probability for 0-HIF1a+/- to control (Fig1D vs. Fig1H). By eye 0-HIF1a+/- mice appear to possess a smaller entry probability than control, when looking at Fig 1D and Fig 1H. However, in the original manuscript the scales on the quantified data (in 1D and 1H) were different. We have revised the Figure 1 to put Fig 1D and 1H on the same scale to remove the illusion for a potential difference and reduce confusion for the reader. Thank you for bring this to our attention.

One assumption is that the LTP in Hif1a+/- mice is due to NMDAr; however, this was not shown (i.e. include AP5). This data needs to be included.

Our Response: We completely agree with the reviewer that we had assumed TBS would evoke NMDAr-dependent LTP in hippocampal slices from HIF1a+/- mice. We have now included an AP5 group in the 10-gHIF1a to illustrate that TBS-LTP was indeed NMDAr-dependent in the HIF1a+/- mice. We have revised the manuscript to reflect this, see lines 256 to 261 and Figure 2D light green symbols.

It is difficult to measure decay time of NMDAr synaptic responses in extracellular recording and there are several problems in the current study.

Our Response: Based on the reviewer's comments we have chosen to replace the analysis of decay time of the fEPSP with amplitude comparisons as suggested by the reviewer. We have revised the manuscript to reflect this, see lines 262 to 276 and Figure 3A-3B.

1\) One problem is the peak amplitudes are vastly different before and after application of AP5 in control mice. Was there a difference in the input/output relationship (AMPAr or NMDAr) between control and Hif1a+/- mice? Was there a difference in input/output curves before and after AP5? At the very least, was there a difference in the maximally evoked fEPSP across mouse strains or due to AP5 application? It appears that AP5 results in a large decrease in the amplitude for the WT control slices (Fig3A). This is not observed for IH10 or Hif1a+/- mice, which suggests fewer NMDARs are at the synapse following IH in WT mice and that synaptic NMDAr levels are low in Hif1a+/- mice regardless of treatment. The question of amplitude differences is also important for interpretation of western blot studies of subunit expression and possible synaptic loss (see Discussion comments).

Our Response: Comparison of maximum amplitudes (evoked by a saturating stimulus current, 700microA) are now replace the decay time measurements of the fEPSP. We did not observe differences between the maximum fEPSP amplitudes generated between in either aCSF or Mg2+-free aCSF. We have revised the manuscript to reflect this, see lines 262 to 276 and Figure 3A and 3B.

In summary, we did not observe differences in the change of fEPSP amplitude in Mg2+-free aCSF from aCSF (Figure 3B) but observed that the reduction of the fEPSP by AP5 was smaller to that of control (Figure 3B). Comparisons of the change in fEPSP of 0-HIF1a+/- and 10-HIF1a+/- to control revealed similar sensitivity to AP5.

2\) Second, in order to measure the true decay, the responses should be normalized to the peak (i.e. peak = 100%). Thus, the peaks in each panel should lineup on the horizontal plane and decay differences would then be evident. In figure 3, the decay is contaminated by differences in the peak.

Our Response: We have replaced this analysis with amplitude analyses to be make this less confusing for the reader. (See above)

Discussion

Missing from the discussion is the mechanism for the decrease in LTP and apparent decrease in the NMADr response. The authors state: our findings indicate that IH reduces receptor expression causing targeted loss of NMDAr-dependent LTP through a HIF1a mediated pro-oxidant mechanism. Implicit in this statement is the assumption that the decrease in LTP is due to a decrease in NMDAr at the synapse.

Our Response: To address the reviewer's concerns, we have made several revisions. Please see below.

First, the authors should discuss whether the reduction in NMDAr expression represents synapse loss, a decreased level of NMDAr at the synapse in the absence of synaptic loss, or loss from intracellular or extrasynaptic compartments. In this case, input/output curves of the fEPSP would help. If the AMPAr component of transmission is not altered, this would suggest no loss of synapses, but does not rule out redox state changes in NMDAr function. If the input/output curve was also decreased, it is possible that there is synaptic loss. In addition, it would have been helpful if the authors had a measure of synaptic number (e.g. PSD95 western blots).

Our Response: We have revised the discussion to reflect many of the reviewer's perspective as we agree. See the revised discussion (Lines 340 to 349. We have also included western blot analysis of PSD-95. We did not find differences in PSD-95 expression.

Second, the authors did not test for a decrease in NMDAr function due to redox state as reported by the Lipton and Foster groups. In this case, the authors would have needed to determine the effects of oxidizing or reducing agents. Thus, this possibility cannot be ruled out.

Our Response: While we did not test for the potential role redox modulation here, we recognize this possibility in the discussion. See the revised discussion (Lines 361 to 369).

Editorial

For figure 1c, distance should be distance to initial entry.

Our Response: We change distance traveled for distance to initial entry

Can the authors supply a better western blot figure 3C? The way the gel ran and the lane difference make it appear as if GluN1 and GAPDH are from different gels.

Our Response: We changed the representative blot for Figure 3C.

Concerning the possibility that IH is acting on unitary conductance of the NMDAr or down regulating the receptor. The authors state: This possibility would not be resolved through further electrophysiological investigation alone. This sentence should be removed or modified. The possibility could be resolved with patch-clamp electrophysiological studies.

Our Response: We agree with this comment and have revised.

These findings indicated that IH-dependent HIF1a signaling suppresses NMDAr expression within the hippocampus, that would contribute to a reduction of NMDAr conductance within individual CA1 neurons. Change to . . . hippocampus, which could . . . The word change, from would to could, is needed since it is not clear that the NMDAr expression represents synaptic receptors.

Our Response: We have revised this passage.

R2:

This study examines the mechanisms and the role of the transcription factor, hypoxia-inducible factor 1a (HIF1a), in cognitive and synaptic function impairment caused by sleep apnea. The rationale is that sleep apnea induces intermittent hypoxia, which is a major mediator of pathophysiology including decline in cognitive and synaptic function. Here, the authors therefore use the Barnes maze that examines hippocampal-dependent spatial memory, brain slice electrophysiology to measure synaptic plasticity in wild type and heterozygous Hif1a mice exposed to intermittent hypoxia and treated with antioxidant, MnTMPyP. In wild type mice, intermittent hypoxia-induced impaired spatial memory was associated with a decline in NMDA receptor dependent LTP and an increase in nuclear factor HIF1a within hippocampus. Intermittent hypoxia-induced HIF1a signaling was also associated with augmented expression of NADPH oxidase 4 and downregulation of GluN1 expression. The intermittent hypoxia-induced effects and HIF1a signaling were not observed in heterozygous for Hif1a or wild type mice treated with MnTMPyP.

The behavioral and physiological results are interesting and the data are surely novel and make a significant contribution. Suggestions for clarification and improvement.

Our Response: We would thank the reviewer for their recognition of the importance of this study and the suggestions for clarification and improvement. Below we have addressed your specific comments.

I would raise the point that of the relationship between the title and the content of the manuscript. The title reads "A HIF1a-dependent pro-oxidant state disrupts synaptic plasticity and impairs spatial memory in a model of sleep apnea" and I was building up to it, to this idea of that "sleep apnea will be induced in these animals at some point before behavioral, synaptic, and other measurements. However, I do not think sleep apnea was induced, rather animals were exposed to intermittent hypoxia, and inclusion of heterozygous Hif1a and treatment with antioxidant. I would suggest a change in the title of the manuscript, something like "A HIF1a-dependent pro-oxidant state disrupts synaptic plasticity and impairs spatial memory in mice". If the authors thinks that heterozygous Hif1a mouse is a model of sleep apnea. In that case, please provide a discussion in the introduction/methods.

Our Response: The protocol of intermittent hypoxia used here is well-accepted to experimental model of sleep apnea. We originally choose to avoid confusion about the use of intermittent hypoxia, as several other paradigms of intermittent hypoxia are not meant to model sleep apnea (e.g., Mitchell GS). However, we can see how that title may be misleading. As such we have revised the title to now state:

A HIF1a-dependent pro-oxidant state disrupts synaptic plasticity and impairs spatial memory in response to intermittent hypoxia.

I am very enthusiastic for the authors to use P50 to P80 mice for delineating the role of HiF1a signaling in intermittent hypoxia induced-alterations in spatial memory and synaptic plasticity. Considering that, these are very young animals and might be passing just through their developing stage (P50), I am wondering how these findings will be interpreted in relation to adult animals. However, if for whatever reasons of available time/availability of adult animals/commitments, and you are not in a position currently to employ advanced age animals, then I would suggest please provide a short discussion in that perspective.

Our Response: We have not revised the manuscript to provide a limited discussion about our perspective of using younger versus older animals (See Lines 370 to 375). As discussed, we find it interesting that IH seems to mimic the change from NMDA receptor dependent to NMDA receptor independent synaptic plasticity observed with aging. We also stress the importance of examining how IH may affect aged animals.

NMDA receptor is a heterotetramer, consisting of GluN1, an obligatory subunit and GluN2A-D subunit as optional ones. In my opinion, inclusion of expression profile of GluN2A/GluN2B in the current study will definitely make it more interesting and overall status of subunit expression profile during intermittent hypoxia.

Our Response: These experiments would enhance our understanding of what is occurring in response to IH among WT animals. As such, we were working on this issue. However, we have not had the opportunity to finish these experiments before laboratory closure due to COVID-19. We ask that the reviewer and editor consider our situation. We do not feel that identifying how NR2A-D subunits are affected by IH should prevent our work from being published at this time. We plan to address this in a future study as soon as we return. Thank you for your consideration in this matter.

Minor Points

1\) Expand and abbreviate NMDAr (line 43), N-methyl-D-aspartate receptor (NMDAr). Our Response: We revised as suggested. See line 82

2\) Abbreviate "the field excitatory postsynaptic potential" at first use (fEPSP) (line 97). Our Response: We revised as suggested. See line 142.

3\) Expand PCNA at first use (line 119), Proliferating Cell Nuclear Antigen.

Our Response: We revised as suggested. See line 166 to 167.

4\) Expand and abbreviate long-term potentiation (LTP) at first use (line 109).

Our Response: We revised as suggested. See line 45.

5\) Delete "changed" from "protein carbonyl content was elevated in IH10 yet unchanged changed in homogenates" (line 231).

Our Response: We revised as requested.

6\) Same at line 236, "elevated in IH10 yet unchanged changed in homogenates from either 0-HIF1a+/- or 10-HIF1a+/":

Our Response: We revised as requested.

7\) Expand and abbreviate DMOG at first use (line 271) in case you are using the same again, Dimethyloxalylglycine (DMOG).

Our Response: We revised as suggested. See line 329.

8\) Be consistent with the use of MnTMPyP, in line 286, it is written MnTMyPyP.

Our Response: Thank you for seeing this. We have reviewed the document for inconsistencies.

9\) Add an arrow for HFS/TBS, indicating start of stimulation paradigm for induction of LTP, in figure 2.

Our Response: We revised as requested

10\) Both side of hippocampi from a mouse were included for Western blot and carbonyl protein analysis or hippocampus was isolated into ventral hippocampus, CA3, CA1, and DG, and region-specific tissues were pooled together? Please provide details in method section.

Our Response: We did not discriminate between ventral or dorsal hippocampus or left/right. For more details in methodology. See line 163-165.

11\) Change reactive oxygen species to ROS (line 277).

Our Response: We revised as suggested. See line 352.

12\) It might be worth including citations by Bodhinathan et al, 2010, Journal of Neuroscience; Haxaire et al 2012, Aging Cell; Kumar and Foster 2013, Journal of Neuroscience, which would enhance the author's point that modulation of oxidative state can influence NMDA receptor synaptic function and spatial memory (line 287).

Our Response: Thank you for suggesting these references. We have now included Bodhinathan et al (2010) and Kumar and Foster (2013) in the discussion as they seemed to be the most relevant to our work. See line (Lines 353 to 359).

13\) Please use expanded version of IP-3 receptor at first use, Inositol 1,4,5-trisphosphate (IP3) receptor (line 292).

Our Response: We changed. See line 363.

14\) Editorials, "approach to enhancing HIF1a" approach to enhance (line 272); "by which sleep apnea may lower of the threshold for cognitive impairment\", delete of (line 301-2)? Our Response: This is no longer present in our revision. Thank you.
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